TABLE OF CONTENTS
1 INTRODUCTION 46
1.1 OBJECTIVES OF THE STUDY 46
1.2 MARKET DEFINITION 46
1.3 OVERVIEW OF THE NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET 46
1.4 LIMITATIONS 48
1.5 MARKETS COVERED 48
2 MARKET SEGMENTATION 51
2.1 MARKETS COVERED 51
2.2 GEOGRAPHICAL SCOPE 52
2.3 YEARS CONSIDERED FOR THE STUDY 53
2.4 CURRENCY AND PRICING 53
2.5 DBMR TRIPOD DATA VALIDATION MODEL 54
2.6 MULTIVARIATE MODELLING 57
2.7 PRODUCT TYPE LIFELINE CURVE 57
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 58
2.9 DBMR MARKET POSITION GRID 59
2.10 MARKET TESTING TYPE COVERAGE GRID 61
2.11 VENDOR SHARE ANALYSIS 62
2.12 SECONDARY SOURCES 63
2.13 ASSUMPTIONS 63
3 EXECUTIVE SUMMARY 64
4 PREMIUM INSIGHTS 67
4.1 PESTEL ANALYSIS 68
4.2 PORTERS FIVE FORCES 69
4.3 GROWTH STRATEGIES ADOPTED BY KEY MARKET PLAYERS 70
5 EPIDEMIOLOGY 71
6 REGULATORY FRAMEWORK OF THE NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET 72
6.1 REGULATORY SCENARIO IN THE U.S. 72
6.2 REGULATORY SCENARIO IN AUSTRALIA 73
6.3 REGULATORY SCENARIO IN JAPAN 73
6.4 REGULATORY SCENARIO IN CHINA 73
7 MARKET OVERVIEW 74
7.1 DRIVERS 76
7.1.1 RISING INCIDENCE AND PREVALENCE OF THYROID NODULES AND CANCER 76
7.1.2 RISING THYROID CANCER DIAGNOSTIC TESTS 76
7.1.3 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UPS 77
7.1.4 RISING AWARENESS TOWARDS THYROID CANCER 77
7.2 RESTRAINTS 78
7.2.1 HIGH COST OF DIAGNOSTICS PROCEDURE 78
7.2.2 TISSUE DAMAGE DUE TO HIGH RADIATION EXPOSURE FROM IMAGING TESTS 79
7.3 OPPORTUNITIES 79
7.3.1 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT 79
7.3.2 RISING OBESE POPULATION 80
7.4 CHALLENGES 80
7.4.1 STRINGENT REGULATORY FRAMEWORK FOR THE APPROVAL AND COMMERCIALIZATION OF CANCER DIAGNOSTIC PRODUCTS 80
7.4.2 LACK OF SKILLED AND CERTIFIED EXPERTISE 81
8 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE 82
8.1 OVERVIEW 83
8.2 INSTRUMENTS 86
8.2.1 PATHOLOGY BASED INSTRUMENTS 87
8.2.1.1 PCR INSTRUMENTS 87
8.2.1.2 SLIDE STAINING SYSTEMS 87
8.2.1.3 TISSUE PROCESSING SYSTEMS 87
8.2.1.4 CELL PROCESSORS 88
8.2.1.5 OTHER PATHOLOGY-BASED INSTRUMENTS 88
8.2.2 IMAGING INSTRUMENTS 88
8.2.2.1 ULTRASOUND SYSTEMS 88
8.2.2.2 CT SYSTEMS 88
8.2.2.3 MRI SYSTEMS 88
8.2.2.4 OTHERS 88
8.2.3 BIOPSY INSTRUMENTS 89
8.2.3.1 NEEDLE BIOPSY 89
8.2.3.2 ENDOSCOPIC BIOPSY 89
8.2.3.3 CORE BIOPSY 89
8.2.3.4 OTHERS 89
8.2.4 OTHERS 89
8.3 CONSUMABLES & ACCESSORIES 90
8.3.1 KITS 91
8.3.1.1 PCR KITS 91
8.3.1.2 DNA POLYMERASE KITS 91
8.3.1.3 NUCLEIC ACID ISOLATION KITS 91
8.3.1.4 OTHERS 91
8.3.2 REAGENTS 92
8.3.2.1 ASSAYS 92
8.3.2.2 BUFFERS 92
8.3.2.3 PRIMERS 92
8.3.2.4 OTHERS 92
8.3.3 PROBES 92
8.3.4 OTHER CONSUMABLES 92
9 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE 93
9.1 OVERVIEW 94
9.2 IMAGING TEST 97
9.2.1 COMPUTED TOMOGRAPHY (CT) SCAN 98
9.2.2 MRI 98
9.2.3 POSITRON EMISSION TOMOGRAPHY (PET) SCAN 98
9.2.4 OTHERS 98
9.3 BLOOD TEST 99
9.3.1 BLOOD CHEMISTRY TESTS 100
9.3.2 COMPLETE BLOOD COUNT (CBC) 100
9.3.3 OTHERS 100
9.4 BIOPSY 100
9.4.1 NEEDLE BIOPSY 101
9.4.2 BRONCHOSCOPY BIOPSY 101
9.4.3 CORE BIOPSY 101
9.4.4 OTHERS 101
9.5 OTHERS 102
10 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET, BY CANCER TYPE 103
10.1 OVERVIEW 104
10.2 PAPILLARY CARCINOMA 107
10.3 FOLLICULAR CARCINOMA 108
10.4 OTHERS 109
11 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET, BY STAGES 110
11.1 OVERVIEW 111
11.2 STAGE I 114
11.3 STAGE II 115
11.4 STAGE III 116
11.5 STAGE IV 117
12 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET, BY AGE GROUP 118
12.1 OVERVIEW 119
12.2 30-65 122
12.3 65 AND ABOVE 123
12.4 21-29 124
12.5 BELOW 21 125
13 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET, BY END USER 126
13.1 OVERVIEW 127
13.2 HOSPITALS 130
13.3 ASSOCIATED LABS 131
13.4 INDEPENDENT DIAGNOSTIC LABORATORIES 131
13.5 DIAGNOSTIC IMAGING CENTERS 132
13.6 CANCER RESEARCH INSTITUTES 133
13.7 OTHERS 134
14 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 135
14.1 OVERVIEW 136
14.2 DIRECT TENDER 139
14.3 RETAIL SALES 140
15 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET, BY REGION 141
15.1 NORTH AMERICA 142
15.1.1 U.S. 152
15.1.2 CANADA 157
15.1.3 MEXICO 162
16 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET: COMPANY LANDSCAPE 167
16.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 167
17 SWOT ANALYSIS 168
18 COMPANY PROFILE 169
18.1 CANON INC. 169
18.1.1 COMPANY SNAPSHOT 169
18.1.2 COMPANY SHARE ANALYSIS 169
18.1.3 PRODUCT PORTFOLIO 170
18.1.4 RECENT DEVELOPMENTS 170
18.2 FUJIFILM CORPORATION 171
18.2.1 COMPANY SNAPSHOT 171
18.2.2 REVENUE ANALYSIS 171
18.2.3 COMPANY SHARE ANALYSIS 172
18.2.4 PRODUCT PORTFOLIO 172
18.2.5 RECENT DEVELOPMENT 172
18.3 F. HOFFMANN-LA ROCHE LTD 173
18.3.1 COMPANY SNAPSHOT 173
18.3.2 REVENUE ANALYSIS 173
18.3.3 COMPANY SHARE ANALYSIS 174
18.3.4 PRODUCT PORTFOLIO 174
18.3.5 RECENT DEVELOPMENT 174
18.4 QUEST DIAGNOSTICS INCORPORATED 175
18.4.1 COMPANY SNAPSHOT 175
18.4.2 REVENUE ANALYSIS 175
18.4.3 COMPANY SHARE ANALYSIS 176
18.4.4 PRODUCT PORTFOLIO 176
18.4.5 RECENT DEVELOPMENTS 176
18.5 ILLUMINA, INC. 178
18.5.1 COMPANY SNAPSHOT 178
18.5.2 REVENUE ANALYSIS 178
18.5.3 COMPANY SHARE ANALYSIS 179
18.5.4 PRODUCT PORTFOLIO 179
18.5.5 RECENT DEVELOPMENT 179
18.6 ABBOTT 180
18.6.1 COMPANY SNAPSHOT 180
18.6.2 REVENUE ANALYSIS 180
18.6.3 PRODUCT PORTFOLIO 181
18.6.4 RECENT DEVELOPMENT 181
18.7 BD 182
18.7.1 COMPANY SNAPSHOT 182
18.7.2 REVENUE ANALYSIS 182
18.7.3 PRODUCT PORTFOLIO 183
18.7.4 RECENT DEVELOPMENT 183
18.8 BEIJING O&D BIOTECH CO., LTD. 184
18.8.1 COMPANY SNAPSHOT 184
18.8.2 PRODUCT PORTFOLIO 184
18.8.3 RECENT DEVELOPMENTS 184
18.9 BIOMRIEUX SA 185
18.9.1 COMPANY SNAPSHOT 185
18.9.2 REVENUE ANALYSIS 185
18.9.3 PRODUCT PORTFOLIO 186
18.9.4 RECENT DEVELOPMENTS 186
18.10 DIASORIN S.P.A. 187
18.10.1 COMPANY SNAPSHOT 187
18.10.2 REVENUE ANALYSIS 187
18.10.3 PRODUCT PORTFOLIO 188
18.10.4 RECENT DEVELOPMENT 188
18.11 FONAR CORP. 189
18.11.1 COMPANY SNAPSHOT 189
18.11.2 REVENUE ANALYSIS 189
18.11.3 PRODUCT PORTFOLIO 190
18.11.4 RECENT DEVELOPMENTS 190
18.12 GENERAL ELECTRIC 191
18.12.1 COMPANY SNAPSHOT 191
18.12.2 REVENUE ANALYSIS 191
18.12.3 PRODUCT PORTFOLIO 192
18.12.4 RECENT DEVELOPMENTS 192
18.13 HOLOGIC INC. 193
18.13.1 COMPANY SNAPSHOT 193
18.13.2 REVENUE ANALYSIS 193
18.13.3 PRODUCT PORTFOLIO 194
18.13.4 RECENT DEVELOPMENT 194
18.14 KONINKLIJKE PHILIPS N.V. 195
18.14.1 COMPANY SNAPSHOT 195
18.14.2 REVENUE ANALYSIS 195
18.14.3 PRODUCT PORTFOLIO 196
18.14.4 RECENT DEVELOPMENT 196
18.15 MERCK KGAA. 197
18.15.1 COMPANY SNAPSHOT 197
18.15.2 REVENUE ANALYSIS 197
18.15.3 PRODUCT PORTFOLIO 198
18.15.4 RECENT DEVELOPMENT 198
18.16 MEDONICA CO. LTD 199
18.16.1 COMPANY SNAPSHOT 199
18.16.2 PRODUCT PORTFOLIO 199
18.16.3 RECENT DEVELOPMENT 199
18.17 MINFOUND MEDICAL SYSTEMS CO. LTD 200
18.17.1 COMPANY SNAPSHOT 200
18.17.2 PRODUCT PORTFOLIO 200
18.17.3 RECENT DEVELOPMENTS 201
18.18 MYRIAD GENETICS, INC. 202
18.18.1 COMPANY SNAPSHOT 202
18.18.2 REVENUE ANALYSIS 202
18.18.3 PRODUCT PORTFOLIO 203
18.18.4 RECENT DEVELOPMENTS 203
18.19 PLEXBIO. 204
18.19.1 COMPANY SNAPSHOT 204
18.19.2 PRODUCT PORTFOLIO 204
18.19.3 RECENT DEVELOPMENTS 204
18.20 QIAGEN 205
18.20.1 COMPANY SNAPSHOT 205
18.20.2 REVENUE ANALYSIS 205
18.20.3 PRODUCT PORTFOLIO 206
18.20.4 RECENT DEVELOPMENT 206
18.21 STERNMED GMBH 207
18.21.1 COMPANY SNAPSHOT 207
18.21.2 PRODUCT PORTFOLIO 207
18.21.3 RECENT DEVELOPMENTS 207
18.22 SIEMENS HEALTHCARE GMBH 208
18.22.1 COMPANY SNAPSHOT 208
18.22.2 REVENUE ANALYSIS 208
18.22.3 PRODUCT PORTFOLIO 209
18.22.4 RECENT DEVELOPMENT 209
18.23 TIME MEDICAL HOLDING. 210
18.23.1 COMPANY SNAPSHOT 210
18.23.2 PRODUCT PORTFOLIO 210
18.23.3 RECENT DEVELOPMENT 210
18.24 THERMO FISHER SCIENTIFIC INC. 211
18.24.1 COMPANY SNAPSHOT 211
18.24.2 REVENUE ANALYSIS 211
18.24.3 PRODUCT PORTFOLIO 212
18.24.4 RECENT DEVELOPMENT 212
19 QUESTIONNAIRE 213

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.